Cargando…

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial

Aims/Introduction: Sulfonylurea (SU) agents are the most effective drugs at lowering blood glucose when used alone. However, their effectiveness declines after a certain period. The addition of liraglutide to existing SU therapy might reverse some of the known drawbacks of SU. Materials and Methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seino, Yutaka, Rasmussen, Mads Frederik, Nishida, Tomoyuki, Kaku, Kohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014968/ https://www.ncbi.nlm.nih.gov/pubmed/24843499 http://dx.doi.org/10.1111/j.2040-1124.2011.00103.x

Ejemplares similares

Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2011)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Sulfonylurea action re‐revisited
por: Seino, Susumu, et al.
Publicado: (2010)

Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality
por: Shimoda, Masashi, et al.
Publicado: (2016)

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Experience with enteral sulfonylurea monotherapy for extremely low birth weight infants with hyperglycemia
por: Nakagawa, Ai, et al.
Publicado: (2022)

Sulfonylureas and their use in clinical practice
por: Sola, Daniele, et al.
Publicado: (2015)

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
por: Wu, Chunjiang, et al.
Publicado: (2015)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018)

Sulfonylureas: Assets in the past, present and future
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sulfonylureas: Scoring beyond START STUDY
por: Shaikh, Altamash
Publicado: (2017)

Sulfonylurea and neuroprotection: The bright side of the moon
por: Hussien, Nawar R., et al.
Publicado: (2018)

The Place of Sulfonylureas in Guidelines: Why Are There Differences?
por: Amod, Aslam
Publicado: (2020)

Latest Evidence on Sulfonylureas: What’s New?
por: Leiter, Lawrence A.
Publicado: (2020)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force”
por: Singh, S. K.
Publicado: (2018)

Sulfonylurea: Personalized Medicine for Type 2 Diabetes
por: Hwang, You-Cheol
Publicado: (2015)

Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
por: Braet, Corey, et al.
Publicado: (2020)

The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
por: Yu, Miao
Publicado: (2020)

Association Between Metformin and Sulfonylurea Monotherapies and Cancer Incidence: A Real-World Cohort Study in Shanghai, China
por: Ye, Jing-Hong, et al.
Publicado: (2019)

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Sulfonylurea Receptor 1 Expression in Human Cerebral Infarcts
por: Mehta, Rupal I., et al.
Publicado: (2013)

Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility
por: Kalra, Sanjay, et al.
Publicado: (2018)

Solvent-Free Synthesis and Safener Activity of Sulfonylurea Benzothiazolines
por: Fu, Ying, et al.
Publicado: (2017)

Protonation and anion-binding properties of aromatic sulfonylurea derivatives
por: Barišić, D., et al.
Publicado: (2021)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
por: Qian, Dan, et al.
Publicado: (2018)

Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis
por: Mekuria, Abraham Nigussie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s0s1d7tjjk8oko418bslc4r88u